Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 3
2007 3
2013 1
2014 3
2016 2
2017 2
2018 2
2019 4
2020 5
2021 4
2022 6
2023 3
2024 11
2025 12
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: konjkavmonfared
Page 1
SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment.
Nakhaei A, Delavar K, Azim AS, Afshari S, Mohtashami A, Jalili-Nik M, Jalali M, Ahmadi SS, Karav S, Afshari AR, Kesharwani P, Sahebkar A. Nakhaei A, et al. Diabetes Res Clin Pract. 2025 Nov;229:112925. doi: 10.1016/j.diabres.2025.112925. Epub 2025 Sep 26. Diabetes Res Clin Pract. 2025. PMID: 41016479 Review.
Recent advances in glioblastoma multiforme therapy: A focus on autophagy regulation.
Sanati M, Binabaj MM, Ahmadi SS, Aminyavari S, Javid H, Mollazadeh H, Bibak B, Mohtashami E, Jamialahmadi T, Afshari AR, Sahebkar A. Sanati M, et al. Biomed Pharmacother. 2022 Nov;155:113740. doi: 10.1016/j.biopha.2022.113740. Epub 2022 Sep 24. Biomed Pharmacother. 2022. Retraction in: Biomed Pharmacother. 2026 Jun 24:119688. doi: 10.1016/j.biopha.2026.119688. PMID: 36166963 Free article. Retracted. Review.
Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial.
Abbasi Kasbi N, Rezaei A, Montazeri R, Nikkhah Bahrami S, Rezaeimanesh N, Arab Bafrani M, Ghane Ezabadi S, Kohandel K, Khodaie F, Jahani S, Naser Moghadasi A, Azimi Saeen A, Navardi S, Heidari H, Ebadi Z, Sahraian MA. Abbasi Kasbi N, et al. Mult Scler J Exp Transl Clin. 2025 Aug 10;11(3):20552173251359074. doi: 10.1177/20552173251359074. eCollection 2025 Jul-Sep. Mult Scler J Exp Transl Clin. 2025. PMID: 40799203 Free PMC article.
64 results